Bellicum Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
April 26 2017 - 7:00AM
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in
developing novel, controllable cellular immunotherapies for cancers
and orphan inherited blood disorders, today announced
that Rick Fair, President and CEO, is scheduled
to present a corporate overview at the Deutsche Bank
42nd Annual Health Care Conference on Wednesday, May 3
at 2:10 p.m. EDT in Boston, Massachusetts.
A live webcast of the presentation may be accessed
from the News & Events section of the Bellicum
website. An archived version of the webcast will be available for
replay for at least two weeks following the event.
About Bellicum
Pharmaceuticals Bellicum is a clinical stage
biopharmaceutical company focused on discovering and developing
cellular immunotherapies for cancers and orphan inherited blood
disorders. Bellicum is using its proprietary Chemical Induction of
Dimerization (CID) technology platform to engineer and control
components of the immune system. Bellicum is developing
next-generation product candidates in some of the most important
areas of cellular immunotherapy, including hematopoietic stem cell
transplantation (HSCT), and CAR-T and TCR cell therapies. More
information can be found at www.bellicum.com.
Investors:
Bellicum Pharmaceuticals
Alan Musso, CFO
832-384-1116
amusso@bellicum.com
Media:
BMC Communications
Brad Miles
646-513-3125
bmiles@bmccommunications.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Sep 2023 to Sep 2024